Equities

Mayinglong Pharmaceutical Group Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Mayinglong Pharmaceutical Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)27.54
  • Today's Change-0.09 / -0.33%
  • Shares traded4.00m
  • 1 Year change+8.81%
  • Beta1.0260
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Mayinglong Pharmaceutical Group Co Ltd is a China-based company mainly engaged in the production and sale of anorectal health products. The Company operates three segments. The Pharmaceutical Industry segment is mainly engaged in the development, production and sale of pharmaceuticals and health products. The Pharmaceutical Commerce segment is mainly engaged in the retail and wholesale of medical devices and pharmaceuticals. The Hospital Diagnosis and Treatment segment is mainly engaged in hospital medical services and management. The Company mainly conducts businesses within the domestic market.

  • Revenue in CNY (TTM)3.77bn
  • Net income in CNY571.60m
  • Incorporated1994
  • Employees2.65k
  • Location
    Mayinglong Pharmaceutical Group Co LtdNo. 100, Nanhu Zhoujiawan, WuchangWUHAN 430064ChinaCHN
  • Phone+86 2 787291519
  • Fax+86 2 787291724
  • Websitehttps://www.mayinglong.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.90bn498.69m10.95bn2.03k21.723.52--5.761.601.606.139.840.34130.93063.06936,748.908.907.1913.049.6766.6459.3026.0820.280.92816.070.460435.8957.2134.33148.1952.7631.58--
Aurisco Pharmaceutical Co Ltd1.62bn424.54m11.02bn1.78k25.644.34--6.781.061.064.076.260.41881.094.41910,578.1010.9411.3712.6013.2959.7752.9326.1322.343.01635.150.280631.5316.8920.4722.5913.7749.45--
Shanghai Yizhong Pharmaceutical Co Ltd247.05m22.96m11.16bn65.00477.127.64--45.180.11320.11321.227.070.1630.95562.263,800,801.001.515.441.585.6481.3992.999.3036.907.84--0.0032.30-51.83---95.68--10.96--
Zhejiang CONBA Pharmaceutical Co., Ltd.6.58bn687.99m11.51bn8.26k17.031.62--1.750.26650.26652.542.800.66172.574.70796,529.007.138.519.6512.7451.8858.6410.7714.121.38--0.053241.54-3.23-0.75945.21--1.57--
Cansino Biologics Inc971.83m-142.03m11.63bn1.11k--3.08--11.97-0.5455-0.54553.9221.370.12710.58611.38879,482.50-1.86-4.08-2.29-5.3878.8045.31-14.62-27.513.29--0.2242--137.01226.4374.45--31.38--
Chengdu Easton Biopharmaceuticals Co Ltd1.33bn241.37m11.90bn1.52k49.114.15--8.951.371.377.5516.230.38091.835.89873,161.506.928.098.449.8271.9081.7218.1620.103.12--0.044430.3720.827.345.1517.014.24--
Mayinglong Pharmaceutical Group Co Ltd3.77bn571.60m11.91bn2.65k20.842.77--3.161.331.338.759.970.72116.2311.991,421,812.0011.3810.7713.8213.3546.7742.4015.7814.394.58--0.022637.3118.856.6219.147.9734.4718.98
Jiangxi Tianxin Pharmaceutical Co Ltd2.23bn617.04m11.94bn2.68k19.262.49--5.361.421.425.1110.930.39732.439.65830,883.1011.0117.1011.8821.1643.0442.9927.7230.124.31--0.072124.4117.351.7536.85-2.2035.06--
Zhejiang Hisun Pharmaceutical Co., Ltd.9.84bn546.80m12.55bn7.99k21.911.47--1.280.47780.47788.617.100.6233.085.321,230,310.003.482.335.814.3246.6441.265.583.990.66465.330.280329.47-5.65-2.44745.2445.22-26.0333.24
Henan Lingrui Pharmaceutical Co., Ltd.3.78bn799.61m12.56bn2.44k15.713.87--3.321.411.416.675.730.7111.898.061,553,625.0015.0811.9025.5218.8979.2674.3621.2116.460.9053--0.137973.975.7210.1727.1919.6714.2924.57
Shenzhen Chipscreen Biosciences Co Ltd850.99m7.28m12.79bn1.06k1,754.907.72--15.030.01790.01792.094.060.24412.404.06802,822.700.20890.00360.24790.004285.4891.310.85570.01811.79-0.63190.48340.0025.6330.51-228.97--15.08--
Beijing Foyou Pharma Co Ltd3.42bn463.07m12.84bn3.64k27.123.40--3.760.98630.98637.287.870.7333.279.59938,316.509.9912.5312.8217.6465.1768.0113.6213.022.52--0.007733.163.177.28-0.018817.4435.29--
Data as of Feb 10 2026. Currency figures normalised to Mayinglong Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

18.29%Per cent of shares held by top holders
HolderShares% Held
Fullgoal Fund Management Co., Ltd.as of 30 Jun 202515.88m3.69%
Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 202515.80m3.67%
China Universal Asset Management Co., Ltd.as of 30 Jun 202510.53m2.45%
Bosera Asset Management Co., Ltd.as of 30 Jun 20259.45m2.20%
China Merchants Fund Management Co., Ltd.as of 30 Jun 20258.39m1.95%
UBS Asset Management (Hong Kong) Ltd.as of 31 Oct 20257.49m1.74%
China Southern Asset Management Co., Ltd.as of 30 Jun 20254.54m1.06%
Harvest Fund Management Co., Ltd.as of 30 Jun 20252.47m0.57%
China Asset Management Co., Ltd.as of 30 Jun 20252.08m0.48%
Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 20252.06m0.48%
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.